Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 10/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852263 | 0.82 | PAK4 (0.44) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL343410 | 0.81 | PAK4 (0.54) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL220647 | 0.81 | PAK4 (0.57) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL20943748 | 0.78 | SYK (0.47) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL3993234 | 0.77 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL22079284 | 0.77 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL24350501 | 0.75 | PIK3C3 (0.54) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL4116079 | 0.75 | PAK4 (0.48) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL3852003 | 0.75 | PAK4 (0.43) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL3939475 | 0.74 | PAK4 (0.56) | PAK4PLK4MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008117051-A1 | S-6-METH0XY-2- (2- (3- (PYRIMID-2-YL) IS0XAZ0L-5-YL) PYRROLIDIN-1-YL) -4- (5-METHYL-IH-PYRAZOL-S-YLAMINO) PYRIMIDINE AND POLYMORPHIC FORMS THEREOF AS MODULATORS OF THE INSULIN-LIKE GROWTH | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | UGT2B7, UGT1A7, CYP3A7 | PAK4 802/4885PLK4 1613/4885MEN1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.